{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.0","upperLimit":"92.3","value":"83.6"},{"groupId":"OG001","lowerLimit":"72.8","upperLimit":"94.7","value":"87.7"},{"groupId":"OG002","lowerLimit":"61.0","upperLimit":"87.6","value":"77.4"},{"groupId":"OG003","lowerLimit":"67.1","upperLimit":"92.4","value":"83.7"}]}],"title":"24 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.6","upperLimit":"83.7","value":"71.7"},{"groupId":"OG001","lowerLimit":"58.7","upperLimit":"86.8","value":"76.0"},{"groupId":"OG002","lowerLimit":"51.1","upperLimit":"80.9","value":"68.6"},{"groupId":"OG003","lowerLimit":"59.6","upperLimit":"88.1","value":"77.4"}]}],"title":"36 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.5","upperLimit":"76.5","value":"62.7"},{"groupId":"OG001","lowerLimit":"58.7","upperLimit":"86.8","value":"76.0"},{"groupId":"OG002","lowerLimit":"44.1","upperLimit":"75.7","value":"62.0"},{"groupId":"OG003","lowerLimit":"47.8","upperLimit":"80.4","value":"66.9"}]}],"title":"48 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.8","upperLimit":"73.6","value":"59.2"},{"groupId":"OG001","lowerLimit":"52.1","upperLimit":"83.8","value":"71.2"},{"groupId":"OG002","lowerLimit":"44.1","upperLimit":"75.7","value":"62.0"},{"groupId":"OG003","lowerLimit":"40.1","upperLimit":"74.4","value":"59.5"}]}],"title":"60 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.8","upperLimit":"73.6","value":"59.2"},{"groupId":"OG001","lowerLimit":"46.3","upperLimit":"80.6","value":"66.5"},{"groupId":"OG002","lowerLimit":"39.8","upperLimit":"72.7","value":"58.2"},{"groupId":"OG003","lowerLimit":"35.7","upperLimit":"71.1","value":"55.2"}]}],"title":"72 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.1","upperLimit":"67.0","value":"50.9"},{"groupId":"OG001","lowerLimit":"46.3","upperLimit":"80.6","value":"66.5"},{"groupId":"OG002","lowerLimit":"27.4","upperLimit":"65.2","value":"47.5"},{"groupId":"OG003","lowerLimit":"30.4","upperLimit":"67.1","value":"50.2"}]}],"title":"84 Months (n=43,44,44,42)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"42"}],"units":"Participants"}],"description":"PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to \\> 20,000/mm\\^3 or an increase by \\> 50,000/mm\\^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 100 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.\n\nAfter the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG000","title":"100mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.","id":"OG001","title":"140mg QD"},{"description":"Participants received 50 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.","id":"OG002","title":"50mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.","id":"OG003","title":"70mg BID"}],"paramType":"NUMBER","populationDescription":"All randomized imatinib-intolerant participants with available data were summarized","reportingStatus":"POSTED","timeFrame":"24, 36, 48, 60, 72, and 84 months","title":"Percent of Imatinib Intolerant Participants With Progression Free Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-Up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}